Analysts Set GSK plc (LON:GSK) PT at GBX 1,805.83

Shares of GSK plc (LON:GSK) have been assigned an average recommendation of “Moderate Buy” from the seven brokerages that are covering the stock, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating, one has given a hold rating and five have issued a buy rating on the company. The average 1 year price target among analysts that have covered the stock in the last year is GBX 1,805.83 ($22.32).

A number of research analysts have weighed in on the company. Berenberg Bank reduced their target price on GSK from GBX 1,820 ($22.49) to GBX 1,600 ($19.77) and set a “buy” rating on the stock in a report on Friday, November 29th. JPMorgan Chase & Co. reaffirmed an “underweight” rating on shares of GSK in a research note on Tuesday, January 7th.

Insider Buying and Selling

In other news, insider Jonathan Symonds acquired 1,500 shares of GSK stock in a transaction on Friday, December 20th. The stock was acquired at an average cost of GBX 1,315 ($16.25) per share, for a total transaction of £19,725 ($24,375.93). 1.61% of the stock is currently owned by company insiders.

GSK Price Performance

Shares of LON:GSK opened at GBX 1,465.50 ($18.11) on Friday. The firm’s 50-day simple moving average is GBX 1,358.76. The stock has a market cap of £59.79 billion, a P/E ratio of 1,296.90, a PEG ratio of 1.24 and a beta of 0.31. The company has a debt-to-equity ratio of 123.04, a quick ratio of 0.73 and a current ratio of 0.82. GSK has a 1 year low of GBX 1,282.50 ($15.85) and a 1 year high of GBX 1,823.50 ($22.53).

GSK (LON:GSK) last posted its earnings results on Wednesday, February 5th. The company reported GBX 23.20 ($0.29) earnings per share (EPS) for the quarter. GSK had a return on equity of 33.30% and a net margin of 12.83%. Analysts expect that GSK will post 175.980975 EPS for the current fiscal year.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.